Annual Report 2013
Merck logo (to the Merck website)
  • Share
  • Corporate Responsibility
  • Dividend
  • Result
  • Employees
  • Sales
  • Divisions
  • Strategy
  • Executive Board
Home· | Merck Group· | Contact· | Deutsch · | Sitemap· | Search
your search: Sales
Relevance of hit 1% back to search result index | New search

  • Index
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34

Notes to the consolidated income statement Audited

  • [22] Sales
  • [23] Royalty, license and commission income
  • [24] Cost of sales
  • [25] Marketing and selling expenses
  • [26] Royalty, license and commission expenses
  • [27] Administration expenses
  • [28] Other operating expenses and income
  • [29] Research and development costs
  • [30] Amortization of intangible assets
  • [31] Financial result
  • [32] Income tax
  • [33] Non-controlling interest
  • [34] Earnings per share
previous hitsearch hit 43 of 74next hit

CHART GENERATOR

Interactive chart tool

SERVICES

  • Recommend page
  • Print page
  • Compare to 2012
  • Order online
  • Glossary
  • Downloads
previous hitsearch hit 43 of 74next hit
 
Imprint, © Merck KGaA, Darmstadt, Germany, Last Update 2014/03/06
  • Transformation on track
    • Letter from Karl-Ludwig Kley
  • Group Management Report
    • Fundamental Information about the Group
      • Divisions
        • Merck Serono
        • Consumer Health
        • Performance Materials
        • Merck Millipore
      • Objectives and strategies
        • Principles and Group strategy
        • Business strategies of the divisions
      • Internal management system
        • Group and Division KPIs
      • Research and Development
        • Consumer Health
    • Report on Economic Position
      • Macroeconomic environment
      • Review of forecast
      • Course of business and economic position
        • Business development
        • Expenses
        • Result
        • Assets and liabilities
        • Overall assessment
      • Merck Serono
        • Business development
        • Regions
        • Major products
        • Expenses
        • Result
      • Consumer Health
        • Business development
        • Regions
        • Expenses
        • Result
      • Performance Materials
        • Business development
        • Regions
        • Expenses
        • Result
      • Merck Millipore
        • Business development
        • Regions
        • Business units
        • Expenses
        • Result
      • Corporate and Other
    • Report on Risks and Opportunities
      • Business-related risks and opportunities
      • Risks and opportunities of product quality and availability
      • Financial risks and opportunities
      • Legal risks
    • Report on Expected Developments
      • Merck Group
      • Merck Serono
      • Consumer Health
      • Performance Materials
      • Merck Millipore
      • Summary
  • Corporate Governance
    • Report of the Supervisory Board
    • Objectives of the Supervisory Board
  • Financial Statements
    • Income Statement
  • Notes
    • Scope of consolidation
      • Changes in the scope of consolidation
    • Accounting policies
      • Management judgments and sources of estimation uncertainty
      • Consolidation methods
      • Recognition of sales and other revenue
      • Financial instruments: Principles
    • Notes to the consolidated income statement
      • Sales
      • Cost of sales
      • Marketing and selling expenses
      • Royalty, license and commission expenses
      • Other operating expenses and income
      • Amortization of intangible assets
    • Notes to the balance sheet
      • Trade accounts payable
      • Provisions
    • Segment reporting
      • Information by division/country and region
      • Information on segment reporting
    • Other disclosures
      • Derivative financial instruments
      • Personnel expenses/Headcount
      • Material costs
  • Business Development 2009-2013
made by Nexxar - your next annual report online!, Vienna - Austria